Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 2/20 | 0.32 |
| ▸ | COMT | P21964 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19425993 | 0.88 | MAPT (0.34) | ALDH1A1SMN1; SMN2MAPTALOX5BCHE | |
| SCHEMBL17191827 | 0.84 | MAPT (0.47) | ALDH1A1MAPTALOX5BCHETYR | |
| SCHEMBL15680165 | 0.82 | TYR (0.33) | ALDH1A1TYRCOMT | |
| SCHEMBL15680468 | 0.78 | TYR (0.37) | MAPTBCHETYRCOMT | |
| SCHEMBL20125111 | 0.75 | FFAR1 (0.41) | ALDH1A1SMN1; SMN2MAPTTYRCOMT | |
| SCHEMBL20626001 | 0.75 | MAPT (0.33) | ALDH1A1SMN1; SMN2MAPTPOLBCYP2C19 | |
| SCHEMBL15680168 | 0.73 | TYR (0.32) | TYR | |
| SCHEMBL12968429 | 0.72 | TYR (0.38) | TYRCOMT | |
| SCHEMBL15680210 | 0.71 | TYR (0.35) | TYRCOMT | |
| SCHEMBL9664988 | 0.70 | COMT (0.40) | TYRCOMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174053-B2 | 2 substituted cephem compounds | GLAXO GROUP LIMITED (GB) | 2019-01-08 | — | — | US | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | CEP170, CES2, CMBL | ALDH1A1 1437/4885SMN1; SMN2 4325/4885MAPT 1744/4885 |
| US-10174053-B2 | 2 substituted cephem compounds | CEP170, CES2, CMBL | ALDH1A1 1437/4885SMN1; SMN2 4325/4885MAPT 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.